2. Signaling Pathways
  3. Membrane Transporter/Ion Channel
  4. Monoamine Transporter
  5. Monoamine Transporter Inhibitor

Monoamine Transporter Inhibitor

Monoamine Transporter Inhibitors (23):

Cat. No. Product Name Effect Purity
  • HY-N0480
    Reserpine
    		Inhibitor 99.83%
    Reserpine is an inhibitor of the vesicular monoamine transporter 2 (VMAT2).
  • HY-B0590
    Tetrabenazine
    		Inhibitor 98.23%
    Tetrabenazine (Ro 1-9569) is a reversible inhibitor of the vesicular monoamine transporter VMAT2 with the Kd value of 1.34 nM. Tetrabenazine can be used for research on diseases related to hyperactive movement disorders such as Huntington's disease.
  • HY-16771
    Valbenazine
    		Inhibitor 98.91%
    Valbenazine (NBI-98854) is a vesicular monoamine transporter 2 (VMAT2) inhibitor with the Ki of 110-190 nM.
  • HY-N0480A
    Reserpine hydrochloride
    		Inhibitor 99.90%
    Reserpine hydrochloride is an inhibitor of the vesicular monoamine transporter 2 (VMAT2).
  • HY-17590
    Radafaxine hydrochloride
    		Inhibitor 98.92%
    Radafaxine hydrochloride (GW-353162A) is a DAT (dopamine transporter) and NET(norepinephrine transporter) transporters inhibitor, and nAChR family modulator.
  • HY-B1704
    Nisoxetine
    		Inhibitor 98.28%
    Nisoxetine is a potent and selective inhibitor of noradrenaline transporter (NET), with a Kd of 0.76 nM. Nisoxetine is an antidepressant and local anesthetic, it can block voltage-gated sodium channels.
  • HY-148863
    Cavα2δ1&NET-IN-2
    		Inhibitor
    Cavα2δ1&NET-IN-2 (Compound 45CS) is a dual inhibitor of the α2δ‑1 subunit of voltage-gated calcium channels (Cavα2δ-1) and the norepinephrine transporter (NET). Cavα2δ1&NET-IN-2 inhibits Cavα2δ-1 with a Ki of 454 nM. Cavα2δ1&NET-IN-2 inhibits NET with a Ki of 59 nM and IC50 of 7 nM. Cavα2δ1&NET-IN-2 can be used for research of pain.
  • HY-148862
    Cavα2δ1&NET-IN-1
    		Inhibitor
    Cavα2δ1&NET-IN-1 (Compound 59S) is a dual inhibitor of the α2δ‑1 subunit of voltage-gated calcium channels (Cavα2δ-1) and the norepinephrine transporter (NET). Cavα2δ1&NET-IN-1 inhibits Cavα2δ-1 with a Ki of 112 nM. Cavα2δ1&NET-IN-1 inhibits NET with a Ki of 383 nM and IC50 of 67 nM. Cavα2δ1&NET-IN-1 can be used for research of pain.
  • HY-15793
    NBI-98782
    		Inhibitor 98.73%
    NBI-98782(alpha-dihydrotetrabenazine) is a vesicular monoamine transporter (VMAT2) inhibtior with an Ki value of 0.97 nM.
  • HY-B0590B
    (+)-Tetrabenazine
    		Inhibitor 99.95%
    (+)-Tetrabenazine ((+)-TBZ; (3R,11bR)-TBZ; (3R,11bR)-Tetrabenazine) is a reversible inhibitor of vesicular monoamine transporter 2 (VMAT-2), inhibits transport by VMAT2 with 10-fold greater potency than transport by VMAT1.
  • HY-B0590S
    Tetrabenazine-d6
    		Inhibitor ≥99.0%
    Tetrabenazine-d6 is the deuterium labeled Tetrabenazine, which is a VMAT-inhibitor used for treatment of hyperkinetic movement disorder.
  • HY-B1704A
    Nisoxetine hydrochloride
    		Inhibitor 99.81%
    Nisoxetine hydrochloride is a potent and selective inhibitor of noradrenaline transporter (NET), with a Kd of 0.76 nM. Nisoxetine hydrochloride is an antidepressant and local anesthetic, it can block voltage-gated sodium channels.
  • HY-B0590A
    Tetrabenazine Racemate
    		Inhibitor ≥98.0%
    Tetrabenazine Racemate (Ro 1-9569 Racemate) is a selective and reversible inhibitor of vesicular monoamine transporter-2 (VMAT-2).
  • HY-B0590E
    Tetrabenazine mesylate
    		Inhibitor
    Tetrabenazine (Ro 1-9569) mesylate is a reversible inhibitor of the vesicular monoamine transporter VMAT2 with the Kd value of 1.34 nM. Tetrabenazine mesylate can be used for research on diseases related to hyperactive movement disorders such as Huntington's disease.
  • HY-16771A
    Valbenazine tosylate
    		Inhibitor
    Valbenazine tosylate (NBI-98854 tosylate) is a vesicular monoamine transporter 2 (VMAT2) inhibitor with the Ki of 110-190 nM.
  • HY-103465
    FFN511
    		Inhibitor
    FFN511 is a potent fluorescent false neurotransmitters (FFNs) that targets neuronal vesicular monoamine transporter 2 (VMA T2). FFN511 inhibits serotonin binding to VMA T2-containing membranes with an IC50 of 1 µM. FFN511 directly images the dynamics of release during exocytosis, can be used to label dopamine terminals in live cortical-striatalacute slices.
  • HY-N0480S
    Reserpine-d9
    		Inhibitor
    Reserpine-d9 is the deuterium labeled Reserpine. Reserpine is an inhibitor of the vesicular monoamine transporter 2 (VMAT2).
  • HY-G0025
    Tetrabenazine Metabolite
    		Inhibitor
    Tetrabenazine Metabolite is an active metabolite of Tetrabenazine. Tetrabenazine Metabolite is a vesicular monoamine transporter 2 (VMAT2) inhibitor with a high affinity (Ki=13.4 nM). Tetrabenazine Metabolite is be developed for the treatment of chorea associated with Huntington’s disease and other hyperkinetic disorders.
  • HY-107740
    Pseudoisocyanine iodide
    		Inhibitor
    Pseudoisocyanine (iodide) is a pan inhibitor of monoamine transporters and organic cation transporters with antidepressant-like activity.
  • HY-117883
    GZ-793A
    		Inhibitor
    GZ-793A is an orally active and selective vesicular monoamine transporter-2 (VMAT2) inhibitor, with an Ki of 0.029 µM. GZ-793A inhibits the neurochemical effects of methamphetamine (METH)-induced dopamine release. GZ-793A can be used for research of METH addiction.